Report Detail
Global Diabetes Drugs Market Insights, Forecast to 2025
- RnM2703767 |
- 28 February, 2019 |
- Global |
- 126 Pages |
- QYResearch |
- Pharma & Healthcare
Diabetes is a condition that keeps your body from making enough insulin. Insulin is a hormone that’s made by an organ called the pancreas. When the body doesn’t make enough insulin, sugar builds up in the blood instead of moving to cells and being used for energy. This causes blood sugar to be high. If blood sugar stays high for a long time, it can cause serious health problems – including blindness, kidney damage, heart disease and stroke. That’s why it’s important to take medicine that helps lower blood sugar levels. Diabetes can be managed so you can live a normal, healthy life.
All diabetes drugs work to lower the levels of sugar in the blood. There are two basic types of diabetes drugs: pills by mouth and shots injected into the skin. More than one drug is often needed to manage diabetes. Some people try different pills, take more than one pill, or take a pill along with shots.
As World overall economic downward trend in the past few years, and international economic situation is complicated, in the next few years there will be many uncertainties, coupled with diabetes drug industry in short supply on the market in the past few years, more companies will enter into the diabetes drug industry, the current demand for diabetes drug product is relatively high; comparing to the ordinary diabetes drug products selling on the market. Diabetes drug’s price remains in the same level as compared with the past years. The signal of market price change indicates the trend in the diabetes drug industry, the market still have large potential.
The global Diabetes Drugs market is valued at 57000 million US$ in 2018 and will reach 87000 million US$ by the end of 2025, growing at a CAGR of 5.4% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Diabetes Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Diabetes Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Diabetes Drugs in these regions.
This research report categorizes the global Diabetes Drugs market by top players/brands, region, type and end user. This report also studies the global Diabetes Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Sanofi
Novo Nordisk
MSD
Astrazeneca
Takeda
Novartis
North China Pharmaceutical Group Corporation
Huadong Medicine
Dongbao Pharmaceutical
Hisun Pharmacy
KELUN
Ginwa
Tianan Pharmaceutical
Jumpcan Pharmacy
Guangzhou Baiyun Mountain
SHIJIAZHUANG YILING PHARMACEUTICAL
Wanbang Biopharmaceuticals
Gan & Lee
Taloph
Market size by Product
Sulphonylureas
Biguanides
Meglitinides
Thiazolidinediones
Alpha-glucosidase Inhibitors
DPP-4 Inhibitors
SGLT-2 Inhibitors
Market size by End User
Application I
Application II
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Diabetes Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Diabetes Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Diabetes Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Diabetes Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Diabetes Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Diabetes Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Diabetes Drugs Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Diabetes Drugs Market Size Growth Rate by Product
- 1.4.2 Sulphonylureas
- 1.4.3 Biguanides
- 1.4.4 Meglitinides
- 1.4.5 Thiazolidinediones
- 1.4.6 Alpha-glucosidase Inhibitors
- 1.4.7 DPP-4 Inhibitors
- 1.4.8 SGLT-2 Inhibitors
- 1.5 Market by End User
- 1.5.1 Global Diabetes Drugs Market Size Growth Rate by End User
- 1.5.2 Application I
- 1.5.3 Application II
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Diabetes Drugs Market Size
- 2.1.1 Global Diabetes Drugs Revenue 2014-2025
- 2.1.2 Global Diabetes Drugs Sales 2014-2025
- 2.2 Diabetes Drugs Growth Rate by Regions
- 2.2.1 Global Diabetes Drugs Sales by Regions
- 2.2.2 Global Diabetes Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Diabetes Drugs Sales by Manufacturers
- 3.1.1 Diabetes Drugs Sales by Manufacturers
- 3.1.2 Diabetes Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Diabetes Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Diabetes Drugs Revenue by Manufacturers
- 3.2.1 Diabetes Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Diabetes Drugs Revenue Share by Manufacturers (2014-2019)
- 3.3 Diabetes Drugs Price by Manufacturers
- 3.4 Diabetes Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Diabetes Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Diabetes Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Diabetes Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Diabetes Drugs Sales by Product
- 4.2 Global Diabetes Drugs Revenue by Product
- 4.3 Diabetes Drugs Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Diabetes Drugs Breakdown Data by End User
6 North America
- 6.1 North America Diabetes Drugs by Countries
- 6.1.1 North America Diabetes Drugs Sales by Countries
- 6.1.2 North America Diabetes Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Diabetes Drugs by Product
- 6.3 North America Diabetes Drugs by End User
7 Europe
- 7.1 Europe Diabetes Drugs by Countries
- 7.1.1 Europe Diabetes Drugs Sales by Countries
- 7.1.2 Europe Diabetes Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Diabetes Drugs by Product
- 7.3 Europe Diabetes Drugs by End User
8 Asia Pacific
- 8.1 Asia Pacific Diabetes Drugs by Countries
- 8.1.1 Asia Pacific Diabetes Drugs Sales by Countries
- 8.1.2 Asia Pacific Diabetes Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Diabetes Drugs by Product
- 8.3 Asia Pacific Diabetes Drugs by End User
9 Central & South America
- 9.1 Central & South America Diabetes Drugs by Countries
- 9.1.1 Central & South America Diabetes Drugs Sales by Countries
- 9.1.2 Central & South America Diabetes Drugs Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Diabetes Drugs by Product
- 9.3 Central & South America Diabetes Drugs by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Diabetes Drugs by Countries
- 10.1.1 Middle East and Africa Diabetes Drugs Sales by Countries
- 10.1.2 Middle East and Africa Diabetes Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Diabetes Drugs by Product
- 10.3 Middle East and Africa Diabetes Drugs by End User
11 Company Profiles
- 11.1 Sanofi
- 11.1.1 Sanofi Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Sanofi Diabetes Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Sanofi Diabetes Drugs Products Offered
- 11.1.5 Sanofi Recent Development
- 11.2 Novo Nordisk
- 11.2.1 Novo Nordisk Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Novo Nordisk Diabetes Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Novo Nordisk Diabetes Drugs Products Offered
- 11.2.5 Novo Nordisk Recent Development
- 11.3 MSD
- 11.3.1 MSD Company Details
- 11.3.2 Company Business Overview
- 11.3.3 MSD Diabetes Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 MSD Diabetes Drugs Products Offered
- 11.3.5 MSD Recent Development
- 11.4 Astrazeneca
- 11.4.1 Astrazeneca Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Astrazeneca Diabetes Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Astrazeneca Diabetes Drugs Products Offered
- 11.4.5 Astrazeneca Recent Development
- 11.5 Takeda
- 11.5.1 Takeda Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Takeda Diabetes Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Takeda Diabetes Drugs Products Offered
- 11.5.5 Takeda Recent Development
- 11.6 Novartis
- 11.6.1 Novartis Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Novartis Diabetes Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Novartis Diabetes Drugs Products Offered
- 11.6.5 Novartis Recent Development
- 11.7 North China Pharmaceutical Group Corporation
- 11.7.1 North China Pharmaceutical Group Corporation Company Details
- 11.7.2 Company Business Overview
- 11.7.3 North China Pharmaceutical Group Corporation Diabetes Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 North China Pharmaceutical Group Corporation Diabetes Drugs Products Offered
- 11.7.5 North China Pharmaceutical Group Corporation Recent Development
- 11.8 Huadong Medicine
- 11.8.1 Huadong Medicine Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Huadong Medicine Diabetes Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Huadong Medicine Diabetes Drugs Products Offered
- 11.8.5 Huadong Medicine Recent Development
- 11.9 Dongbao Pharmaceutical
- 11.9.1 Dongbao Pharmaceutical Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Dongbao Pharmaceutical Diabetes Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Dongbao Pharmaceutical Diabetes Drugs Products Offered
- 11.9.5 Dongbao Pharmaceutical Recent Development
- 11.10 Hisun Pharmacy
- 11.10.1 Hisun Pharmacy Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Hisun Pharmacy Diabetes Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Hisun Pharmacy Diabetes Drugs Products Offered
- 11.10.5 Hisun Pharmacy Recent Development
- 11.11 KELUN
- 11.12 Ginwa
- 11.13 Tianan Pharmaceutical
- 11.14 Jumpcan Pharmacy
- 11.15 Guangzhou Baiyun Mountain
- 11.16 SHIJIAZHUANG YILING PHARMACEUTICAL
- 11.17 Wanbang Biopharmaceuticals
- 11.18 Gan & Lee
- 11.19 Taloph
12 Future Forecast
- 12.1 Diabetes Drugs Market Forecast by Regions
- 12.1.1 Global Diabetes Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Diabetes Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Diabetes Drugs Market Forecast by Product
- 12.2.1 Global Diabetes Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Diabetes Drugs Revenue Forecast by Product 2019-2025
- 12.3 Diabetes Drugs Market Forecast by End User
- 12.4 North America Diabetes Drugs Forecast
- 12.5 Europe Diabetes Drugs Forecast
- 12.6 Asia Pacific Diabetes Drugs Forecast
- 12.7 Central & South America Diabetes Drugs Forecast
- 12.8 Middle East and Africa Diabetes Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Diabetes Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Diabetes Drugs . Industry analysis & Market Report on Diabetes Drugs is a syndicated market report, published as Global Diabetes Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Diabetes Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
